ArticleBMJ open2026

Real-world impact of SGLT2 inhibitors on the risk of symptomatic urinary tract infections in patients with cardiometabolic and kidney diseases: a prospective, multicentre, observational cohort study protocol.

Shuai Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.